BRPI0912717A2 - Composição farmacêutica, e, uso de 5-azacitidina - Google Patents

Composição farmacêutica, e, uso de 5-azacitidina

Info

Publication number
BRPI0912717A2
BRPI0912717A2 BRPI0912717-8A2A BRPI0912717A BRPI0912717A2 BR PI0912717 A2 BRPI0912717 A2 BR PI0912717A2 BR PI0912717 A BRPI0912717 A BR PI0912717A BR PI0912717 A2 BRPI0912717 A2 BR PI0912717A2
Authority
BR
Brazil
Prior art keywords
azacytidine
pharmaceutical composition
pharmaceutical
composition
Prior art date
Application number
BRPI0912717-8A2A
Other languages
English (en)
Inventor
Jeffrey B Etter
Mei Lai
Jay Thomas Backstrom
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40941609&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0912717(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of BRPI0912717A2 publication Critical patent/BRPI0912717A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
BRPI0912717-8A2A 2008-05-15 2009-05-14 Composição farmacêutica, e, uso de 5-azacitidina BRPI0912717A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US5360908P 2008-05-15 2008-05-15
US20114508P 2008-12-05 2008-12-05
US15787509P 2009-03-05 2009-03-05
PCT/US2009/002999 WO2009139888A1 (en) 2008-05-15 2009-05-14 Oral formulations of cytidine analogs and methods of use thereof

Publications (1)

Publication Number Publication Date
BRPI0912717A2 true BRPI0912717A2 (pt) 2014-12-23

Family

ID=40941609

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0912717-8A2A BRPI0912717A2 (pt) 2008-05-15 2009-05-14 Composição farmacêutica, e, uso de 5-azacitidina

Country Status (34)

Country Link
US (11) US8846628B2 (pt)
EP (6) EP4327888A2 (pt)
JP (3) JP2011520880A (pt)
KR (1) KR101633134B1 (pt)
CN (3) CN102099018B (pt)
AR (1) AR071808A1 (pt)
AU (3) AU2009246926B2 (pt)
BR (1) BRPI0912717A2 (pt)
CA (3) CA3094590A1 (pt)
CL (2) CL2009001170A1 (pt)
CO (1) CO6300930A2 (pt)
CR (1) CR11789A (pt)
CY (3) CY1121350T1 (pt)
DK (5) DK3782611T3 (pt)
EC (1) ECSP10010665A (pt)
ES (4) ES2893785T3 (pt)
FI (1) FI3782612T3 (pt)
HR (5) HRP20221064T1 (pt)
HU (5) HUE042825T2 (pt)
IL (2) IL209307A (pt)
LT (5) LT3782612T (pt)
MX (2) MX363023B (pt)
MY (1) MY161593A (pt)
NI (1) NI201000193A (pt)
NZ (3) NZ602833A (pt)
PE (2) PE20091971A1 (pt)
PL (5) PL2695609T3 (pt)
PT (5) PT2299984T (pt)
RU (3) RU2476207C2 (pt)
SG (1) SG193206A1 (pt)
SI (5) SI2299984T1 (pt)
TW (3) TW201513869A (pt)
WO (1) WO2009139888A1 (pt)
ZA (1) ZA201008229B (pt)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8404717B2 (en) * 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes using lenalidomide
US8404716B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US11116782B2 (en) 2002-10-15 2021-09-14 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US6943249B2 (en) 2003-03-17 2005-09-13 Ash Stevens, Inc. Methods for isolating crystalline Form I of 5-azacytidine
US6887855B2 (en) 2003-03-17 2005-05-03 Pharmion Corporation Forms of 5-azacytidine
US8497292B2 (en) 2005-12-28 2013-07-30 Translational Therapeutics, Inc. Translational dysfunction based therapeutics
WO2009058394A1 (en) * 2007-11-01 2009-05-07 Celgene Corporation Cytidine analogs for treatment of myelodysplastic syndromes
US20150290228A1 (en) * 2008-05-15 2015-10-15 Jay T. BACKSTROM Oral formulations of cytidine analogs and methods of use thereof
SG193206A1 (en) * 2008-05-15 2013-09-30 Celgene Corp Oral formulations of cytidine analogs and methods of use thereof
WO2010093435A1 (en) 2009-02-10 2010-08-19 Celgene International Sarl Methods for treating non-small cell lung cancer using 5-azacytidine
US8491927B2 (en) * 2009-12-02 2013-07-23 Nimble Epitech, Llc Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
US20110301102A1 (en) * 2010-06-07 2011-12-08 Telik, Inc. Compositions and methods for treating myelodysplastic syndrome
US8759303B2 (en) 2010-06-07 2014-06-24 Telik, Inc. Compositions and methods for treating myelodysplastic syndrome
MY166014A (en) * 2010-06-07 2018-05-21 Abraxis Bioscience Llc Combination therapy methods for treating proliferative diseases
CA2825152A1 (en) * 2011-01-31 2012-08-09 Celgene Corporation Pharmaceutical compositions of cytidine analogs and methods of use thereof
EP2481813A1 (en) * 2011-02-01 2012-08-01 Centro di Riferimento Oncologico - Istituto Nazionale Tumori - Aviano Markers of cutaneous melanoma and uses thereof
US9951098B2 (en) 2011-03-31 2018-04-24 Pharmion Llc Synthesis of 5-azacytidine
JP6162709B2 (ja) * 2011-11-01 2017-07-12 セルジーン コーポレイション シチジンアナログの経口製剤を使用して癌を治療する方法
CN104245699B (zh) 2011-11-03 2017-06-27 米伦纽姆医药公司 Nedd8‑活化酶抑制剂和低甲基化剂的投与
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
WO2014015153A2 (en) * 2012-07-20 2014-01-23 Star Biotechnology, Llc Compositions and methods for treating ewing's sarcoma and other disorders related to ews-fli1
US20150031627A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
EA036325B1 (ru) 2014-03-14 2020-10-27 Аджиос Фармасьютикалз, Инк. Фармацевтическая композиция на основе твердой дисперсии ингибитора idh1
US20150359810A1 (en) * 2014-06-17 2015-12-17 Celgene Corporation Methods for treating epstein-barr virus (ebv) associated cancers using oral formulations of 5-azacytidine
BR112017003620A2 (pt) 2014-08-22 2017-12-05 Celgene Corp métodos de tratamento de mieloma múltiplo com compostos imunomoduladores em combinação com anticorpos
EA036129B1 (ru) * 2015-10-15 2020-10-01 Селджин Корпорейшн Комбинированная терапия для лечения злокачественных новообразований
KR20180061372A (ko) 2015-10-15 2018-06-07 아지오스 파마슈티컬스 아이엔씨. 악성 종양의 치료를 위한 조합물 요법
LT3362066T (lt) * 2015-10-15 2022-02-10 Les Laboratoires Servier Sas Kombinuota terapija, skirta piktybinių susirgimų gydymui
EP3960182A1 (en) 2015-12-03 2022-03-02 Epidestiny, Inc. Compositions containing decitabine, 5-azacytidine and tetrahydrouridine and uses thereof
US11035850B2 (en) 2016-04-12 2021-06-15 The Johns Hopkins University Quantitative determination of nucleoside analogue drugs in genomic DNA or RNA
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
EA039874B1 (ru) * 2019-06-06 2022-03-22 Общество С Ограниченной Ответственностью "Технология Лекарств" Композиция помалидомида для лечения заболеваний, ассоциированных с фактором некроза опухоли (фно)
US20220249528A1 (en) 2019-06-20 2022-08-11 Celgene Corporation Azacitidine in combination with venetoclax, gilteritinib, midostaurin or other compounds for treating leukemia or myelodysplastic syndrome
BR112022007179A2 (pt) 2019-10-21 2022-08-23 Novartis Ag Inibidores de tim-3 e usos dos mesmos
WO2021079188A1 (en) 2019-10-21 2021-04-29 Novartis Ag Combination therapies with venetoclax and tim-3 inhibitors
US20230056470A1 (en) 2019-12-20 2023-02-23 Novartis Ag Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
US20230058489A1 (en) 2020-01-17 2023-02-23 Novartis Ag Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
BR112023001236A2 (pt) 2020-07-23 2023-04-04 Southern Res Inst Polimorfos de 5-aza-4'-tio-2-desoxicitidina
US11858956B2 (en) 2020-12-18 2024-01-02 Southern Research Institute 6-aza-nucleoside prodrugs as antiviral agents for treating virus infections
WO2022192621A1 (en) 2021-03-12 2022-09-15 Celgene Corporation Methods for using a hypomethylating agent to treat diseases and disorders based on gene mutation profiles
WO2023069529A1 (en) 2021-10-19 2023-04-27 Akirabio, Inc. Compositions comprising 2'-deoxycytidine analogs and use thereof for the treatment of sickle cell disease, thalassemia, and cancers

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2913408A (en) 1956-12-28 1959-11-17 Dow Chemical Co Corrosion inhibitors for ferrous metals in aqueous solutions of non-oxidizing acids
GB1050899A (pt) 1963-12-22
CH527207A (de) 1968-05-08 1972-08-31 Ceskoslovenska Akademie Ved Verfahren zur Herstellung von 1-Glycosyl-5-azacytosinen
CH507969A (de) 1968-11-12 1971-05-31 Ceskoslovenska Akademie Ved Verfahren zur Herstellung von 1-Glycosyl-5-azacytosinen
DE2012888C3 (de) 1970-03-14 1981-04-02 Schering Ag, 1000 Berlin Und 4619 Bergkamen Verfahren zur Herstellung von 5-Azapyrimidinnucleosiden
FR2123632A6 (en) 1971-01-26 1972-09-15 Ceskoslovenska Akademie Ved Prepn of 5-azacytosines and 5-azacytidines - from bis trimethylsilyl-5-azacytosine
DE2122991C2 (de) 1971-05-04 1982-06-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen Verfahren zur Herstellung von Cytosin- und 6-Azacytosinnucleosiden
DE2508312A1 (de) 1975-02-24 1976-09-02 Schering Ag Neues verfahren zur herstellung von nucleosiden
DE2757365A1 (de) 1977-12-20 1979-06-21 Schering Ag Neues verfahren zur herstellung von nucleosiden
JPS59151784U (ja) 1983-03-30 1984-10-11 日産自動車株式会社 トラツクのリヤボデイ構造
US5391485A (en) 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
JPS63500636A (ja) 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
DE59009525D1 (de) 1989-05-10 1995-09-21 Hoffmann La Roche Herstellung von Isochinolinderivaten.
US5360352A (en) 1992-12-24 1994-11-01 The Whitaker Corporation Wire retainer for current mode coupler
US6432924B1 (en) 1993-12-26 2002-08-13 East Carolina University Method of treating disorders characterized by overexpression of cytidine deaminase or deoxycytidine deaminase
GB9412394D0 (en) 1994-06-21 1994-08-10 Danbiosyst Uk Colonic drug delivery composition
US5700640A (en) 1994-09-16 1997-12-23 Basf Aktiengesellschaft Inducers of gamma globin gene expression and screening assays therefor
US5539209A (en) 1994-10-17 1996-07-23 Trojan Technologies Inc. Method of cleaning fouling materials from a radiation module
WO1998016186A2 (en) 1996-10-16 1998-04-23 Icn Pharmaceuticals, Inc. Monocyclic l-nucleosides, analogs and uses thereof
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
PT998271E (pt) 1997-06-06 2005-10-31 Depomed Inc Formas de dosagem oral de farmacos com retencao gastrica para a libertacao controlada de farmacos altamente soluveis
US6566395B1 (en) 1999-05-25 2003-05-20 Biomedicines, Inc. Methods of treating proliferative disorders
US6803195B1 (en) 1999-07-02 2004-10-12 Ramot At Tel-Aviv University Ltd. Facile detection of cancer and cancer risk based on level of coordination between alleles
US6890547B1 (en) 1999-07-16 2005-05-10 Amato Pharmaceutical Products, Ltd. Glycyrrhizin preparations for transmucosal absorption
PT1251832E (pt) 2000-02-04 2007-01-31 Depomed Inc Forma de dosagem constituída por invólucro-e-núcleo que conduz a uma libertação do fármaco de ordem zero
GB0102342D0 (en) 2001-01-30 2001-03-14 Smithkline Beecham Plc Pharmaceutical formulation
EP1399159A4 (en) 2001-06-01 2007-02-14 Cytovia Inc 4-SUBSTITUTE-1- (ARYLMETHYLIDENE) THIOSEMICARBAZIDE, 4-SUBSTITUTE-1- (ARYLCARBONYL) THIOSEMICARBAZIDE AND ANALOGUES AS ACTIVATORS OF APOPTOSIS CAPSASES AND TRIGS, AND USE THEREOF
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
US20030220254A1 (en) 2002-03-29 2003-11-27 Texas Tech University System Composition and method for preparation of an oral dual controlled release formulation of a protein and inhibitor
US7772197B2 (en) 2002-09-24 2010-08-10 1,3,5-Triazines for Treatment of Viral Diseases 1,3,5-triazines for treatment of viral diseases
US7189740B2 (en) * 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
EP1556010A4 (en) 2002-10-31 2007-12-05 Supergen Inc PHARMACEUTICAL FORMULATIONS TARGETING SPECIFIC REGIONS OF THE GASTROINTESTINAL TRACT
CN100364531C (zh) 2002-12-18 2008-01-30 西托维亚公司 3,5－二取代－[1,2,4]－二唑及类似物和其用途
US6943249B2 (en) 2003-03-17 2005-09-13 Ash Stevens, Inc. Methods for isolating crystalline Form I of 5-azacytidine
US7038038B2 (en) 2003-03-17 2006-05-02 Pharmion Corporation Synthesis of 5-azacytidine
US6887855B2 (en) 2003-03-17 2005-05-03 Pharmion Corporation Forms of 5-azacytidine
CN1964714B (zh) * 2003-08-29 2011-09-28 Hdac默克研究有限责任公司 辛二酰苯胺异羟肟酸和吉西他滨在制备用于治疗癌症的药物中的用途
US7192781B2 (en) 2004-04-13 2007-03-20 Pharmion Corporation Methods for stabilizing 5-azacytidine in plasma
US20060063735A1 (en) 2004-09-17 2006-03-23 Supergen, Inc. Salts of 5-azacytidine
US20060069060A1 (en) 2004-09-27 2006-03-30 Sanjeev Redkar Salts of decitabine
CN100374160C (zh) * 2004-11-22 2008-03-12 山东蓝金生物工程有限公司 一种含抗代谢类药物的抗癌药物组合物
US20060128654A1 (en) 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of cytidine analogs and derivatives
MX2007009960A (es) 2005-02-18 2008-03-11 Abraxis Bioscience Inc Combinaciones y metodos de administracion de agentes terapeuticos y terapia de combinacion.
AU2006222365B2 (en) 2005-03-07 2011-07-14 Bayer Healthcare Llc Pharmaceutical composition comprising an omega- carboxyaryl substituted diphenyl urea for the treatment of cancer
CN100500212C (zh) * 2005-04-06 2009-06-17 山东蓝金生物工程有限公司 一种抗实体肿瘤药物组合物
US8058260B2 (en) 2006-05-22 2011-11-15 Xenoport, Inc. 2′-C-methyl-ribofuranosyl cytidine prodrugs, pharmaceutical compositions and uses thereof
US20080057086A1 (en) 2006-09-01 2008-03-06 Pharmion Corporation Colon-targeted oral formulations of cytidine analogs
WO2008088779A2 (en) 2007-01-11 2008-07-24 Ivax Pharmaceuticals S.R.O. Solid state forms of 5-azacytidine and processes for preparation thereof
EP2114152A1 (en) 2007-01-25 2009-11-11 Nevada Cancer Institute Use of acetylated or esterificated azacytidine, decitabine, or other nucleoside analogs as oral agents for the treatment of tumors or other dysplastic syndromes sensitive to hypomethylating agents
JP5173298B2 (ja) 2007-07-25 2013-04-03 キヤノン株式会社 プリント配線板およびそれを用いた電子機器
WO2009016617A2 (en) 2007-08-02 2009-02-05 Chemagis Ltd. Stable highly pure azacitidine and preparation methods therefor
NZ583824A (en) 2007-09-26 2012-06-29 Sinai School Medicine Azacytidine analogues and uses thereof
EP2048151A1 (en) 2007-10-10 2009-04-15 Cilag AG Method for producing nucleosides by direct glycosylation of the nucleoside base
JO2778B1 (en) 2007-10-16 2014-03-15 ايساي انك Certain vehicles, installations and methods
WO2009058394A1 (en) 2007-11-01 2009-05-07 Celgene Corporation Cytidine analogs for treatment of myelodysplastic syndromes
SG193206A1 (en) * 2008-05-15 2013-09-30 Celgene Corp Oral formulations of cytidine analogs and methods of use thereof
EP2321302B1 (en) 2008-08-01 2014-10-29 Dr. Reddy's Laboratories Ltd. Azacitidine process and polymorphs
ES2400779T3 (es) 2008-08-06 2013-04-12 Sicor, Inc. Proceso para preparar un producto intermedio de azacitidina
JP5650643B2 (ja) 2008-08-08 2015-01-07 サイノファーム タイワン リミテッド ５−アザシトシンヌクレオシド及びその誘導体の製造方法
JP6041489B2 (ja) 2008-11-22 2016-12-07 ジェネンテック， インコーポレイテッド 乳癌の治療のための化学療法と併用した抗ｖｅｇｆ抗体の使用
US20110042247A1 (en) 2009-06-25 2011-02-24 Chandrasekhar Kocherlakota Formulations of azacitidine and its derivatives
WO2011014541A1 (en) 2009-07-30 2011-02-03 Eagle Pharmaceuticals, Inc. Stable formulations of azacitidine
IT1399195B1 (it) 2010-03-30 2013-04-11 Chemi Spa Processo per la sintesi di azacitidina e decitabina
CA2825152A1 (en) 2011-01-31 2012-08-09 Celgene Corporation Pharmaceutical compositions of cytidine analogs and methods of use thereof
US9951098B2 (en) 2011-03-31 2018-04-24 Pharmion Llc Synthesis of 5-azacytidine
WO2013022872A1 (en) 2011-08-10 2013-02-14 Celgene Corporation Gene methylation biomarkers and methods of use thereof
JP6162709B2 (ja) 2011-11-01 2017-07-12 セルジーン コーポレイション シチジンアナログの経口製剤を使用して癌を治療する方法

Also Published As

Publication number Publication date
HRP20200096T1 (hr) 2020-04-03
US10220050B2 (en) 2019-03-05
EP2695609A1 (en) 2014-02-12
US20090286752A1 (en) 2009-11-19
HRP20231439T1 (hr) 2024-03-01
PL3692983T3 (pl) 2021-12-27
LT3782612T (lt) 2023-12-27
CL2009001170A1 (es) 2010-06-04
JP2015110575A (ja) 2015-06-18
NI201000193A (es) 2011-08-01
RU2018109222A (ru) 2019-09-17
EP3782612B1 (en) 2023-11-08
RU2476207C2 (ru) 2013-02-27
CN103479586B (zh) 2017-03-01
JP2017137326A (ja) 2017-08-10
ZA201008229B (en) 2012-02-29
AU2013202665B2 (en) 2015-06-25
AU2009246926B2 (en) 2014-06-26
EP4327888A2 (en) 2024-02-28
JP2011520880A (ja) 2011-07-21
SI3782612T1 (sl) 2024-02-29
SI2695609T1 (sl) 2020-03-31
KR20110015629A (ko) 2011-02-16
DK3692983T3 (da) 2021-09-20
HRP20190100T1 (hr) 2019-04-05
NZ589437A (en) 2012-11-30
IL209307A (en) 2016-02-29
HUE042825T2 (hu) 2019-07-29
EP2299984B1 (en) 2018-11-28
CR11789A (es) 2011-02-21
AR071808A1 (es) 2010-07-14
PL3782611T3 (pl) 2022-11-07
US20150374732A1 (en) 2015-12-31
CY1122681T1 (el) 2020-10-14
EP3692983A1 (en) 2020-08-12
ES2893785T3 (es) 2022-02-10
HRP20211398T1 (hr) 2021-12-10
SI3692983T1 (sl) 2021-11-30
PL3782612T3 (pl) 2024-03-04
SG193206A1 (en) 2013-09-30
CO6300930A2 (es) 2011-07-21
MX363023B (es) 2019-03-05
US20220079964A1 (en) 2022-03-17
TWI522103B (zh) 2016-02-21
US8846628B2 (en) 2014-09-30
US20150056280A1 (en) 2015-02-26
MY161593A (en) 2017-04-28
CY1121350T1 (el) 2020-05-29
EP3692983B1 (en) 2021-08-11
RU2010151428A (ru) 2012-06-20
PE20091971A1 (es) 2010-01-15
US20180153916A1 (en) 2018-06-07
EP3782611B1 (en) 2022-07-06
TW201729817A (zh) 2017-09-01
AU2015202884B2 (en) 2017-02-23
KR101633134B1 (ko) 2016-06-23
CA3094580C (en) 2021-05-18
HUE055911T2 (hu) 2021-12-28
RU2018109222A3 (pt) 2021-07-02
EP2299984A1 (en) 2011-03-30
PL2695609T3 (pl) 2020-05-18
EP3782611A1 (en) 2021-02-24
RU2012147739A (ru) 2014-05-20
NZ623495A (en) 2015-08-28
CL2013001097A1 (es) 2013-11-29
US20200101095A1 (en) 2020-04-02
TW201006478A (en) 2010-02-16
NZ602833A (en) 2014-04-30
DK3782611T3 (da) 2022-09-05
EP2695609B1 (en) 2019-12-11
WO2009139888A1 (en) 2009-11-19
PE20142440A1 (es) 2015-01-28
CN102099018A (zh) 2011-06-15
CA3094590A1 (en) 2009-11-19
DK2299984T3 (en) 2019-03-04
HUE064677T2 (hu) 2024-04-28
IL238087B (en) 2019-01-31
LT2695609T (lt) 2020-02-10
AU2015202884A1 (en) 2015-06-18
DK3782612T3 (da) 2024-01-15
PT3782612T (pt) 2024-01-18
LT2299984T (lt) 2019-03-25
PT3782611T (pt) 2022-11-18
US11571436B2 (en) 2023-02-07
PT2695609T (pt) 2020-03-02
DK2695609T3 (da) 2020-02-10
HUE047707T2 (hu) 2020-05-28
PT2299984T (pt) 2019-02-25
US10463683B2 (en) 2019-11-05
PT3692983T (pt) 2021-11-08
RU2765076C2 (ru) 2022-01-25
HUE059635T2 (hu) 2022-12-28
CA3094580A1 (en) 2009-11-19
AU2013202665A1 (en) 2013-05-02
US20190231803A1 (en) 2019-08-01
CA2761582A1 (en) 2009-11-19
MX2010012470A (es) 2010-12-02
US20200316099A1 (en) 2020-10-08
PL2299984T3 (pl) 2019-07-31
ECSP10010665A (es) 2011-01-31
EP3782612A1 (en) 2021-02-24
LT3782611T (lt) 2022-10-10
US20230241086A1 (en) 2023-08-03
CY1124720T1 (el) 2022-07-22
TW201513869A (zh) 2015-04-16
SI2299984T1 (sl) 2019-04-30
CN105535008A (zh) 2016-05-04
ES2712506T3 (es) 2019-05-13
US20220105118A1 (en) 2022-04-07
ES2774226T3 (es) 2020-07-17
ES2927556T3 (es) 2022-11-08
JP6105547B2 (ja) 2017-03-29
FI3782612T3 (fi) 2024-01-16
HRP20221064T1 (hr) 2022-11-11
US20230255996A1 (en) 2023-08-17
AU2009246926A1 (en) 2009-11-19
TWI618538B (zh) 2018-03-21
CA2761582C (en) 2022-06-07
CN103479586A (zh) 2014-01-01
CN102099018B (zh) 2016-01-13
LT3692983T (lt) 2021-11-10
IL209307A0 (en) 2011-01-31
JP6426778B2 (ja) 2018-11-21
SI3782611T1 (sl) 2022-10-28
US10646503B2 (en) 2020-05-12

Similar Documents

Publication Publication Date Title
BRPI0912717A2 (pt) Composição farmacêutica, e, uso de 5-azacitidina
BR112012002331A2 (pt) composição antiviral, composição farmacêutica e uso de quantidade efetiva de composição farmacêutica
BRPI0813627A2 (pt) Peptídio antimicrobiano, composições e métodos de uso
BRPI0816350A2 (pt) Composições orais, produtos e métodos de uso
BRPI0917315A2 (pt) anticorpo, composicao farmaceutico, e, uso de uma composicao farmaceutica
BRPI0908792A2 (pt) Composição, e, uso de uma combinação
BRPI0913726A2 (pt) rapalogs, composições farmacêuticas, métodos de preparo e uso dos mesmos
BRPI0821115A2 (pt) Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto
BRPI0919942A2 (pt) Composto, composição farmacêutica, e, uso de um composto
BRPI0907562A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0921375A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0813770A2 (pt) Composição, e, uso de uma composição
BRPI1005292A2 (pt) composição de decapagem e uso da composição
BR112012004335A2 (pt) composto, composição farmacêutica, e, uso do composto.
BRPI0917001A2 (pt) composto, composição farmacêutica, e, uso de um composto ou uma composição farmacêutica
BRPI0819299A2 (pt) Uso de composição, e, composição contendo proteína
BRPI1014316A2 (pt) composição, e, uso de uma composição
BRPI0921879A2 (pt) composto, composição farmacêutica , e, uso de um composto
BRPI0917579A2 (pt) composto, composição farmacêutica, métodos, e, uso de um composto
BR112012031226A2 (pt) composto, uso do composto, composição farmacêutica, e uso de composição farmacêutica
BRPI0921699A2 (pt) complexo antioxidante, composicoes cosmeticas e farmaceutica contendo o referido complexo e uso deste complexo
BRPI0914793A2 (pt) Composição, e, uso de uma composição
BR112012003842A2 (pt) composição farmacêutica, método de formulação e uso da mesma
BRPI0915120A2 (pt) composto derivado de oxima, uso do referido composto e composição farmacêutica
BRPI0906937A2 (pt) composto, composição farmacêutica, e, uso de um composto

Legal Events

Date Code Title Description
B65X Notification of requirement for priority examination of patent application
B65Y Grant of priority examination of the patent application (request complies with dec. 132/06 of 20061117)
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B15W Others matters related to applications: legal action concerning application

Free format text: "INPI NO 52402.009234/2021-26 ORIGEM: JUIZO SUBSTITUTO DA 25A VF DO RIO DE JANEIRO (TRF2) PROCESSO NO: 5084516-58.2021.4.02.5101 NULIDADE DE ATO ADMINISTRATIVO COM PEDIDO DE ANTECIPACAO DE TUTELA AUTOR: CELGENE CORPORATION REU(S): INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL "